Background
Cristina Adriana Popa
Hunting Primary Hyperaldosteronism: are MRAs a ...

This week, we will continue with February’s aldosterone leitmotif: do mineralocorticoid receptor antagonists (MRAs) truly blind the diagnostic in unilateral hypraldosteronism? Is this the article the mythbuster? Draw your own conclusions

Hunting Primary Hyperaldosteronism: are MRAs a blindfold in adrenal vein sampling?
Background
Brian Rifkin
Undercover Aldosterone

This week, we will discuss the origins of primary hyperaldosteronism in normotensive patients. Could this undetected anomaly be the cause of idiopathic hypertension and CKD?

Undercover Aldosterone
Background
swapnil hiremath
HOPE-ing and Coping with Pain in Dialysis

This week, we will discuss the HOPE trial - no not that one - the one in dialysis that was a LBCT in 2024. Should we look beyond analgesics to non-pharmacological options more seriously?

HOPE-ing and Coping with Pain in Dialysis
news
Cristina Adriana Popa
Top Stories in Nephrology 2024

Should we call 2024 the Renaissance of nephrology? It was probably the richest year in RCTs in the nephrology world, reflected in the higher number of Late-Breaking Clinical Trials sessions at every big nephrology congress. Probably 1st place won’t surprise anyone; it was the anticipated FLOW of the year, but this Top 10 Nephrology Stories definitely includes some unexpected titles

Top Stories in Nephrology 2024
Background
Cristina Adriana Popa
ACEing the management of advanced CKD

This week we come to meta-analyse, strikingly late, the cornerstone of all CKD treatments. Are you still in doubt? We need ACEing CKD to the end of GFR, and beyond

ACEing the management of advanced CKD

NOAC

Confusing AF

Now that twitter has recovered from its downtime, a catch-up tweetorial on apixaban for AF in patients on dialysis for you.